OptimizeRx price target lowered to $8 from $16 at JMP Securities
JMP Securities lowered the firm’s price target on OptimizeRx (OPRX) to $8 from $16 and keeps an Outperform rating on the shares.
Acrivon Therapeutics: Promising Clinical Data and Strategic Progress Justify Buy Rating
In a report released yesterday, Etzer Darout from BMO Capital reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research ...